Navigation Links
Shire begins the year with a strong performance
Date:4/30/2009

cludes the effect of certain cash and non-cash items, both recurring and non-recurring, that Shire's management believes are not related to the core performance of Shire's business. A list of these items can be found on pages 23-24.

New Product Launches

Subject to obtaining the relevant regulatory/governmental approvals, product launches planned over the next two years include:

    - MEZAVANT(R) (mesalamine) for the treatment of ulcerative colitis in
      certain EU countries during 2009;

    - FIRAZYR(R) (icatibant) for the symptomatic treatment of acute attacks
      of herediatary angioedema ("HAE") in certain European and Latin
      American countries during 2009;

    - INTUNIV for the treatment of ADHD in children and adolescents in the
      US in the fourth quarter of 2009;

    - DAYTRANA for the treatment of ADHD in adolescents in the US in 2010;

    - Velaglucerase Alfa for the treatment of Gaucher disease in the US and
      the EU in 2010; and

    - VYVANSE for the treatment of ADHD, in ex-US and ex-EU regions starting
      in 2010, and in the EU in 2011.

Additional Information

Dial in details for the live conference call for investors 14:30 BST/09:30 EDT on April 30, 2009:

    UK dial in: 0808-100-5150

    US dial in: 1-866-804-8688 or 1-718-354-1175

    International dial in: +44-(0)1296-480-100

    Password/Conf ID: 228 831

    Webcast:http://www.shire.com/shire/InvestorRelations/index.jsp?tn=2


    OVERVIEW OF US GAAP FINANCIAL RESULTS
    1. Introduction
    Summary of Q1 2009

Revenues from continuing operations for the three months to March 31, 2009 increased by 16% to $817.8 million (2008: $702.2 million).

Non GAAP operating income for the three months to March 31, 2009 increased by 70% to $326.9 m
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Results of the Annual General Meeting Held on April 28, 2009
2. Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009
3. Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
4. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
5. Publication of Shire plcs Annual Report 2008
6. Shires Project Playground Gives Boost to Philadelphia
7. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
8. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
9. Shire Announces Opening of Office in Japan
10. Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
11. Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Vital Imaging ™ has teamed ... San Diego for a joint study which aims to ... Resonance Imaging) with that of a supine Dynawell MRI ... of improved healthcare by combining cutting edge technology with ... valuable tool for evaluating pathological changes in the spine, ...
(Date:5/21/2013)... 21, 2013 PathoGenetix, Inc., a commercial-stage ... typing, announced today that it has successfully identified and ... strains obtained from the Centers for Disease Control and ... technology. The findings are detailed in a poster ... Society for Microbiology in Denver on Monday. , The ...
(Date:5/20/2013)... , Collaboration with the ... in treatment of mastitis , ... to begin in the second half 2013 ... Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) will collaborate ... Service (ARS) to develop and trial products targeting the ...
(Date:5/20/2013)... 2013  MiMedx Group, Inc. (NASDAQ: MDXG ... protected regenerative biomaterials and bioimplants processed from human amniotic ... line of credit with Bank of America.  The revolving ... Company,s accounts receivable and inventory, allows MiMedx to borrow ... facility will be used for general corporate purposes. ...
Breaking Biology Technology:Vital Imaging Makes Greater Commitment into MRI Research 2Vital Imaging Makes Greater Commitment into MRI Research 3New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3Phosphagenics Signs Research Agreement with the Agricultural Research Service 2
... now have a new tool to help diagnose symptomatic patients ... the most common sexually transmitted infections in the world.   ... and Company), announced today that it received U.S. Food and ... molecular tests to detect and differentiate HSV types 1 and ...
... BioTechnologies, Inc. (TriLink) announced that it has entered into ... its CleanAmp™ Products. The Scandinavian based TATAA develops and ... in addition to providing tailor-made products for real-time PCR ... Hot Start PCR, TriLink,s CleanAmp™ Product Line is an ...
... Inc. (OTC Bulletin Board: BONU ), a ... of Dr. Stephen Holt, M.D., Ph.D, a Distinguished Professor ... York State, as the Company,s Vice Chairman of the ... consultant to the pharmaceutical and dietary supplement industry, and ...
Cached Biology Technology:BD Diagnostics Receives FDA Clearance for First Fully Automated Molecular Assays for HSV1 and HSV2 from Clinician-Collected External Anogenital Lesion Specimens 2TriLink Enters Into Distribution Agreement With TATAA Biocenter 2BioNeutral Elects Stephen Holt, M.D., Ph.D as Vice Chairman and Independent Director of the Board 2BioNeutral Elects Stephen Holt, M.D., Ph.D as Vice Chairman and Independent Director of the Board 3
(Date:5/18/2013)... MD (May 19, 2013) The AGA Research Foundation ... and Damian Augustyn Award in Digestive Cancer, which will ... of Medicine at the University of Pennsylvania, Philadelphia, as ... in pancreas development, regeneration and cancer progression. , "The ... in honor of two distinguished clinicians and AGA Legacy ...
(Date:5/18/2013)... Research presented at Digestive Disease Week (DDW) explores ... and lifestyle. , Individuals suffering from Crohn,s ... fatigue and poor quality of life. These symptoms ... A randomized, double blind, placebo-controlled study found for ... to significant relief of these symptoms. , ...
(Date:5/17/2013)... 2013) The AGA Research Foundation announced a new ... between the gut microbiota, one of today,s most exciting ... , The AGA Research Awards Panel selected Andrew T. ... Hospital and Harvard Medical School, Boston, as the 2013 ... will receive $25,000 of funding, commencing in July 2013, ...
Breaking Biology News(10 mins):AGA Research Foundation grant furthers digestive cancer research 2Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3New gut microbiome research to explore red meat -- colorectal cancer pathway 2
... with the hepatitis C virus (HCV) are at an ... lymphatic system), according to a study published in the ... American Medical Association. Researchers from the National Cancer ... and Baylor College of Medicine, found that HCV infection ...
... greatest importance nowadays since it express who we are, but is ... its form? The answer to that question seems to be related ... Universidad Nacional Autonoma de Mexico and the Buck Institute in the ... than fashion. , In biology, the capacity to establish the ...
... Jake Najman and Gail Williams and Stockholm University's Professor Robin ... between 1981 and 2002. , Their results were published ... and Alcohol Review. , The men were categorised ... worker status is a marker for lower socio-economic status (SES). ...
Cached Biology News:Risk of lymphoma increases with hepatitis C virus infection 2Double the death rate from cirrhosis for 'blue collar' men 2
96-well format (For processing samples on microplate-size MALDI target plates such as those from Bruker, Shimadzu, Thermo, and PerkinElmer) Packaging: 2 / pack...
... recombinant IFNA2. Immunogen: Human IFNA2 ... in E. coli. The biological activity was ... OMIM: 147562, GeneID: ... MA Code: ABV0P9DPB ...
Mouse monoclonal antibody raised against a partial recombinant CENTB2. NCBI Entrez Gene ID = CENTB2...
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
Biology Products: